Q4FY26 Audited Financial Results
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gland Pharma reported consolidated revenue from operations of ₹64,306.50 million for FY26, up 14.5% from ₹56,165.04 million in FY25. Profit after tax surged to ₹14,583.03 million from ₹7,539.13 million, representing a 93% year-on-year increase. EPS for FY26 stood at ₹62.35 per share (basic) compared to ₹42.40 in FY25. The statutory auditors (Deloitte Haskins & Sells) issued an unmodified opinion on the annual financial statements. The Board recommended a final dividend of ₹20 per equity share (2000% on face value of ₹1). An exceptional item of ₹243.46 million was recognized due to additional gratuity and leave liability provisions under the new Labour Codes effective November 2025.
Strong PAT growth of 93% YoY significantly exceeds the 25% threshold, indicating robust profitability improvement. The clean audit opinion with no going concern issues reinforces financial health. The dividend of ₹20 per share provides direct shareholder returns.